 |
|
|
| |
3-Year Efficacy and Safety of Tenofovir Alafenamide Compared With Tenofovir Disoproxil Fumarate in HBeAg-Negative and -Positive Patients With Chronic Hepatitis B
|
| |
| |
Reported by Jules Levin
AASLD 2018 Nov 9-13 SF
Henry Lik Yuen Chan,1 Young-Suk Lim,2 Wai Kay Walter Seto,3 Kosh Agarwal,4 Maurizia R. Brunetto,5 Harry L.A. Janssen,6 Florin Caruntu,7 Tatjana Stepanova,8 Owen Tsang,9 Hiroshi Yatsuhashi,10 Won Young Tak,11 Chi-Yi Chen,12 Mustafa Celen,13 Vithika Suri,14 John F. Flaherty,14 Lanjia Lin,14 Andrea Cathcart,14 Anuj Gaggar,14 Calvin Q. Pan,15 Shalimar,16 Maria Buti17
1Institute of Digestive Disease, State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong; 2Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; 3Queen Mary Hospital, Hong Kong; 4Institute of Liver Studies, King's College Hospital NHS Foundation Trust, London, UK; 5Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy; 6Toronto Centre for Liver Disease, University Health Network, Toronto, Ontario, Canada; 7Institutul National de Boli Infectioase "Prof.Dr. Matei Bals," Bucharest, Romania; 8Modern Medicine Clinic, Moscow, Russia; 9Princess Margaret Hospital, Hong Kong; 10National Hospital Organization Nagasaki Medical Center, Nagasaki, Japan; 11Kyungpook National University School of Medicine, Daegu, South Korea; 12Chia-Yi Christian Hospital, Chiayyi, Taiwan; 13Dicle Üniversitesi Medical School Hospitals, Diyarbakir, Turkey; 14Gilead Sciences, Inc., Foster City, CA; 15NYU Langone Medical Center, New York, NY; 16All India Institute of Medical Sciences, New Delhi, India; 17Vall d'Hebron Barcelona Campus Hospitalari, Barcelona, Spain
|
| |
|
|
|
|
|
